---
title: "Berry Genomics controlling shareholder's concerted action on 40,000 shares judicial auction failed to sell"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/257317086.md"
description: "Chengdu Berry Genomics Co., Ltd. announced that 400,000 shares of the company's stock held by its controlling shareholder's concerted actor, Hou Ying, failed to sell at judicial auction on September 12, 2025. This share represents 100% of his holdings and 0.11% of the company's total share capital. As of the announcement date, a total of 19,805,661 shares held by Hou Ying have been subject to judicial auction. The company's production and operations are normal, and this auction has not had a significant adverse impact; the unsold shares will be disposed of according to the court's ruling"
datetime: "2025-09-15T08:28:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/257317086.md)
  - [en](https://longbridge.com/en/news/257317086.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/257317086.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/257317086.md) | [English](https://longbridge.com/en/news/257317086.md)


# Berry Genomics controlling shareholder's concerted action on 40,000 shares judicial auction failed to sell

Chengdu Berry Genomics Co., Ltd. announced that the 400,000 shares of the company held by its controlling shareholder's concerted actor, Hou Ying, were unsold at the judicial auction that ended at 10:00 on September 12, 2025, due to no bids placed within the specified time. This portion of shares accounts for 100.00% of her holdings and 0.11% of the company's total share capital, and they are all unrestricted tradable shares, which have been fully pledged and judicially re-frozen. As of the announcement date, Hou Ying has had a total of 19,805,661 shares of the company auctioned judicially. Currently, the company's production and operations are normal, and this auction has not caused any significant adverse impact. The unsold shares will be disposed of according to the ruling of the Chengdu Financial Court, and the company will continue to disclose updates

### 相關股票

- [Berry Genomics (000710.CN)](https://longbridge.com/zh-HK/quote/000710.CN.md)

## 相關資訊與研究

- [Jacobio Pharma: Differentiated Pan-KRAS Profile, Multiple Clinical Catalysts, and Solid Balance Sheet Underscore Buy Rating](https://longbridge.com/zh-HK/news/278909908.md)
- [12:23 ETFull Circles Therapeutics Highlights Circular Single-Stranded DNA Platform Enabling Immune-Evasive Genome Writing in Nature Study](https://longbridge.com/zh-HK/news/278753990.md)
- [11:41 ETNovafjord Expands Multi-Asset Trading Services With AI-Driven Arbitrage and Risk Management Tools](https://longbridge.com/zh-HK/news/278417992.md)
- [Navigating the PPQ process: Proven strategies to safeguard quality for cell and gene therapies](https://longbridge.com/zh-HK/news/278886282.md)
- [<![CDATA[FDA Approves Leucovorin Without a Clinical Trial for Cerebral Folate Transport Deficiency: Report ]]>](https://longbridge.com/zh-HK/news/278589943.md)